Make a donation

Friday, September 16, 2022

D-Rd Appears to Improve Long-Term Outcomes in Newly Diagnosed, Transplant-Ineligible Myeloma

Among patients with newly diagnosed, transplant-ineligible patients with multiple myeloma (MM), adding daratumumab to lenalidomide and dexamethasone (D-Rd) appears to improve long-term outcomes, according to research presented at the 19th Annual Meeting and Exposition International Myeloma Society.

Read more here.